Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort
- PMID: 16545007
- DOI: 10.1089/aid.2006.22.213
Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort
Abstract
The responses to HAART in HIV-infected adolescents infected through risk behaviors are not well defined. PACTG 381 collected intensive immunologic and virologic data on youth naive to or with minimal exposure to antiretroviral therapy who began HAART. Subjects were evaluated according to their weeks 16-24 virologic response. Comparisons with a cohort of HIV-uninfected adolescents from the REACH cohort were performed. Cox proportional hazards models were used to identify baseline and week 24 predictors of virologic failure. Only 69 of 120 subjects (58%) achieved virologic suppression by weeks 16-24, whereas 55 of 69 (80%) demonstrated control to week 60. Higher CD4+ naive T cells (CD4+/62L+/RA+: hazard ratio [HR], 2.13; p = 0.018), higher CD8+ activated T cells (CD8+/CD38+/DR+: HR, 1.40, p = 0.028 per 100 cells/mm3) and higher CD8+ naive T cells (CD8+/62L+/RA+: HR, 1.72; p = 0.005) at weeks 16-24 in subjects with early viral success were predictive of subsequent failure. By week 60, total CD4+ T cells remained significantly lower than in uninfected controls. Adolescents beginning HAART achieve moderate rates of viral suppression by weeks 16-24. In those who do achieve early virologic control, suppression to week 60 is high although total CD4+ T cells remain significantly lower than in uninfected controls. Several T cell markers were predictive of subsequent virologic failure in subjects achieving short-term success. Further study is warranted to determine whether these predictors provide any benefit to clinical management.
Similar articles
-
Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.J Infect Dis. 2004 Jul 15;190(2):271-9. doi: 10.1086/421521. Epub 2004 Jun 18. J Infect Dis. 2004. PMID: 15216461 Clinical Trial.
-
Long-term observation of adolescents initiating HAART therapy: three-year follow-up.AIDS Res Hum Retroviruses. 2007 Oct;23(10):1208-14. doi: 10.1089/aid.2006.0290. AIDS Res Hum Retroviruses. 2007. PMID: 17961106
-
Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.PLoS One. 2006 Dec 20;1(1):e89. doi: 10.1371/journal.pone.0000089. PLoS One. 2006. PMID: 17183720 Free PMC article. Clinical Trial.
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.AIDS Rev. 2006 Apr-Jun;8(2):88-97. AIDS Rev. 2006. PMID: 16848276 Review.
Cited by
-
The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review.AIDS Res Hum Retroviruses. 2021 Feb;37(2):75-88. doi: 10.1089/AID.2020.0126. Epub 2020 Dec 7. AIDS Res Hum Retroviruses. 2021. PMID: 33176429 Free PMC article. Review.
-
Model-Based Methods to Translate Adolescent Medicine Trials Network for HIV/AIDS Interventions Findings Into Policy Recommendations: Rationale and Protocol for a Modeling Core (ATN 161).JMIR Res Protoc. 2019 Apr 16;8(4):e9898. doi: 10.2196/resprot.9898. JMIR Res Protoc. 2019. PMID: 30990464 Free PMC article.
-
Interest of Youth Living With HIV in Long-Acting Antiretrovirals.J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):190-197. doi: 10.1097/QAI.0000000000001896. J Acquir Immune Defic Syndr. 2019. PMID: 30418298 Free PMC article.
-
Viral suppression and viral rebound among young adults living with HIV in Canada.Medicine (Baltimore). 2018 Jun;97(22):e10562. doi: 10.1097/MD.0000000000010562. Medicine (Baltimore). 2018. PMID: 29851775 Free PMC article.
-
Soluble CD14, CD163, and CD27 biomarkers distinguish ART-suppressed youth living with HIV from healthy controls.J Leukoc Biol. 2018 Apr;103(4):671-680. doi: 10.1002/JLB.3A0717-294RR. Epub 2018 Jan 29. J Leukoc Biol. 2018. PMID: 29377283 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials